Explore /
Poster
/ Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.

Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.

Authors

Apostolia Maria Tsimberidou

The University of Texas MD Anderson Cancer Center, Houston, TX

Apostolia Maria Tsimberidou , Borje Andersson , Chad Stewart , Hong Ma , Oliver Schoor , Dominik Maurer , Claudia Wagner , Arun Satelli , Jens Fritsche , Geoffery L Stephens , Ali Mohamed , Zoe Coughlin , Allie M Stungis , Kshipra M Gharpure , Patrick Hwu , Cassian Yee , Carsten Reinhardt , Steffen Walter , Harpreet Singh , Toni Weinschenk

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Cellular Immunotherapy

Clinical Trial Registration Number

NCT02876510

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS3106)

DOI

10.1200/JCO.2018.36.15_suppl.TPS3106

Abstract #

TPS3106

Poster Bd #

317b

Abstract Disclosures

Similar Posters

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

$Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.$